CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a study on the clinical application of chimeric antigen receptor modified γδ T cells
(CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant
tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell
infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.